Editor\u2019s Take: WuXi has been tallying certifications and clearances for its China facilities in the middle months of 2026.<\/p>\n
WuXi Biologics<\/a>\u2019 MFG8 drug substance manufacturing facility in Hebei, China successfully passed U.S. FDA Pre-License Inspection (PLI). This benchmark supports commercial manufacturing for what the global CRDMO calls a potential \u201cblockbuster\u201d autoimmune therapy.<\/p>\n Exactly what the therapy is has not been disclosed by WuXi Biologics. In acknowledging the inspection, CEO Chris Chen, PhD, said WuXi\u2019s high-quality manufacturing capabilities will help bring the therapy to patients.<\/p>\n Reaction to FDA Inspection<\/p>\n \u201cMFG8\u2019s successful PLI pass is a strong testament to WuXi Biologics\u2019 commitment to global quality and compliance standards,\u201d Chen said. \u201cThis reflects sustained investment in a world-class quality system and proven capability to support partners in advancing global commercial manufacturing \u2026 WuXi Biologics will continue to empower global partners with a reliable quality system and accelerate the delivery of innovative biologics.\u201d<\/p>\n WuXi characterized MFG8 as an important part of its global manufacturing network. The facility is equipped with 12 4000-L single-use bioreactors. The company can accordingly scale out to offer commercial manufacturing from anywhere from 4000 to 20,000 L.<\/p>\n WuXi\u2019s Regulatory Record<\/p>\n Within the last month, four other WuXi Biologics sites have garnered regulatory wins. Two manufacturing facilities and a packaging center, all in WuXi, China, got good manufacturing practice (GMP) certification from Brazil\u2019s ANVISA<\/a>. And the company\u2019s Suzhou Biosafety Testing Center passed a GMP inspection<\/a> by the European Medicines Agency (EMA).<\/p>\n For the FDA inspection in Hebei, which took seven days, three inspectors conducted quality management and drug substance manufacturing checks. Successful passing meant no blemishes to WuXi Biologics\u2019 100% pass rate in FDA PLIs to date.<\/p>\n Not counting the most recent certifications, WuXi Biologics as of the end of 2025 passed 46 regulatory inspections. These include 22 by either the FDA or EMA.<\/p>\n","protected":false},"excerpt":{"rendered":"Editor\u2019s Take: WuXi has been tallying certifications and clearances for its China facilities in the middle months of…\n","protected":false},"author":2,"featured_media":668703,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[4,450,451,3,452,453],"class_list":["post-753226","post","type-post","status-publish","format-standard","has-post-thumbnail","category-breaking-news","tag-breaking-news","tag-breakingnews","tag-headlines","tag-news","tag-top-stories","tag-topstories"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/753226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=753226"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/753226\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/668703"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=753226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=753226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=753226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}